N/A N=2 Safety of 4CMenB Exposure During Pregnancy
Infections, Meningococcal
Primary: Major Congenital Malformation (MCM)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=360 Lifestyle and Pregnancy: The Clinical Effect of Lifestyle Intervention During Pregnancy in Obese Women
Maternal Obesity · Gestational Weight Gain · Obstetric Complications
Primary: Cesarean Section
N/A N=251 Optimisation of the Management of Placental Delivery in Second Trimester Pregnancy Interruption
Placenta, Retained · Postpartum Hemorrhage
Primary: Placental Retention Rate — 26; 8; 24 participants — p=0.05
N/A N=82 Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
Meningococcal Disease · Pregnancy · Infections, Meningococcal
Primary: Percentage of Live Births Reported With Major Congenital Malformations (MCM) on Exposure to Menveo Within 28 Days Prior to Conception — 0.0; 84.6; 15.4 Percentage of…
N/A N=103 Twinrix Pregnancy Registry
Hepatitis
Primary: Number of Outcomes From Pregnancies With Reported Exposure Within 28 Days of Last Menstrual Period — 0; 0; 0; 0 Pregnancy Outcomes
N/A N=16 Acute Exercise Effects in Obese Pregnancy
Pregnancy Complications · Obesity · Pre-Eclampsia
Primary: Oral Glucose Insulin Sensitivity (OGIS) Index — 405.0; 426.0; 418.9 uU/mL
N/A N=120 Monitoring Movement and Health Study
Pregnancy Related · Obesity · Hypertension
Primary: Number of Participants Classified as Having High Sedentary Behavior (by Trajectory) — 45 Participants
N/A N=1,400 Assessment of a Fruit and Vegetable Prescription Program for Children
Exposure to Fruit and Vegetable Prescription Program
Primary: Change From Baseline Child-reported Mean Daily Intake of Fruits and Vegetables at 6 and 12 Months Among Youth Participants Newly Introduced to the FVPP — 0.21; 0.17…
Phase 2 N=30 Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy
Hyperemesis Gravidarum · Nausea Gravidarum · Vomiting of Pregnancy
Primary: Time to Symptom Control — 72; 87 minutes
Phase 2 N=3 Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
Gastrointestinal Inflammation Associated With CVID · CVID Enteropathy
Primary: Number of Participants With Increase in Infection or Serious Adverse Events (SAEs) Related to Single Dose Administration of Ustekinumab — 0 participants
N/A N=120 Personalized Integrated Chronotherapy for Perinatal Depression
Depression · Postpartum Depression · Prenatal Disorder
Primary: Change in Depressive Symptoms — 1.6; 2.2 units on a scale
Phase 3 N=1,703 Chloroquine for Malaria in Pregnancy
Malaria
Primary: Incidence of Placental Malaria Infection Based on Histology — 11.58; 15.42; 15.42 percentage of pregnancies — p=0.2441
Phase 3 N=498 Simplifying the Rabies Pre-exposure Vaccination
Rabies
Primary: Number of Participants With a Boostability of the Rabies Antibodies After Booster Vaccination — 185; 183 Participants
N/A N=3,416 Lamotrigine Pregnancy Registry (LAM05)
Epilepsy · Bipolar Disorder
Primary: Birth Outcomes by Earliest Pregnancy Trimester of Exposure to Lamotrigine Monotherapy — 31; 4; 1; 0 infants
Phase 4 N=14 Effects of Pregnancy-associated Hormones on THC Metabolism in Women
Pregnancy Related · Cannabis Use
Primary: Dronabinol Exposure — 7.0; 5.6; 5.1; 5.0 nM*h — p=>0.05